Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome

Nanjing PLA General Hospital114 enrolled

Overview

The purpose of this study is to investigate the effect of pectin, a kind of soluble dietary fiber, on clinical symptoms, gut microbiota and the immune status in patients with diarrhea-predominant irritable bowel syndrome

Patients were randomized to receive either pectin or placebo. Treatment consisted of 6 weeks supplementation with pectin (fiber group) or placebo (maltodextrin). We evaluated the clinical symptoms, gut microbiota and the immune markers in two groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

114

Conditions

Irritable Bowel Syndrome

Interventions

PectinDIETARY_SUPPLEMENT

Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks

maltodextrinDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients(age≧18y) * Admitted for diarrhea-predominant irritable bowel syndrome Exclusion Criteria: * Mental disorders * Cancer * Inflammatory bowel disease

Outcomes

Primary Outcomes

efficacy: change of stool frequency, faecal form and clinical symptoms score

change from baseline in stool frequency, faecal form (Bristol stool scale) and clinical symptoms score (7-point Likert scale) at six weeks

Time frame: six weeks after inclusion

Secondary Outcomes

efficacy: gut microbiota

real-time PCR

Time frame: six weeks after inclusion

efficacy: cytokine ratios

Cytokine production

Time frame: six weeks after inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.